Our cross-sectional analysis assessed the prevalence of DM/IFG and the MS in a large series of “real-life”, unselected CML-chronic phase patients during TKI treatment and estimated both insulin sensitivity and β-cell function in these individuals. This evidence concerns the gene INS and chronic myelogenous leukemia, BCR-ABL1 positive.